Haya Kaseer1,2, Matthew Soto-Arenall1, Devang Sanghavi3, John Moss3, Robert Ratzlaff3, Si Pham4, Pramod Guru3. 1. Department of Pharmacy, Mayo Clinic, Jacksonville, Florida. 2. Department of Pharmacy, UF Health Shands Hospital, Gainesville, Florida. 3. Department of Critical Care Medicine, Mayo Clinic, Jacksonville, Florida. 4. Department of Cardiothoracic Surgery, Mayo Clinic, Jacksonville, Florida.
Abstract
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) induces hemostatic alterations that may contribute to hematological complications. Unfractionated heparin (UFH) is the mainstay antithrombotic in ECMO and depends on antithrombin III (AT III) to exhibit its actions. However, it bears the risk for heparin-induced thrombocytopenia. Bivalirudin is a direct thrombin inhibitor and is inherently not dependent on AT III. AIM OF THE STUDY: To assess the efficacy and safety profiles of UFH compared with bivalirudin during ECMO support. METHODS: We retrospectively reviewed 52 adult patients who were supported by ECMO from 1 January 2013 to 1 September 2018. Among them, 33 received UFH and 19 received bivalirudin. We analyzed their 7-day rate of composite thrombotic, bleeding, and mortality episodes while on anticoagulation. RESULTS: There were no statistical differences in the 7-day rate of composite thrombosis (33.3% vs 26.3%; P = 0.60), major bleeding (18.2% vs 5.3%; P = .24), 30-day mortality, (42.4% vs 26.3%; P = .37), or in-hospital mortality (45.5% vs 36.8%; P = .58). The percentage of time activated partial thromboplastin time (aPTT) was within the therapeutic range was higher with bivalirudin (50% vs 85.7%; P = .007). CONCLUSIONS: This study suggests that UFH and bivalirudin are associated with similar rates of thrombosis, major bleeding, and mortality events in patients supported by ECMO. However, it was observed that bivalirudin consistently maintained aPTT within the therapeutic range in comparison to UFH.
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) induces hemostatic alterations that may contribute to hematological complications. Unfractionated heparin (UFH) is the mainstay antithrombotic in ECMO and depends on antithrombin III (AT III) to exhibit its actions. However, it bears the risk for heparin-induced thrombocytopenia. Bivalirudin is a direct thrombin inhibitor and is inherently not dependent on AT III. AIM OF THE STUDY: To assess the efficacy and safety profiles of UFH compared with bivalirudin during ECMO support. METHODS: We retrospectively reviewed 52 adult patients who were supported by ECMO from 1 January 2013 to 1 September 2018. Among them, 33 received UFH and 19 received bivalirudin. We analyzed their 7-day rate of composite thrombotic, bleeding, and mortality episodes while on anticoagulation. RESULTS: There were no statistical differences in the 7-day rate of composite thrombosis (33.3% vs 26.3%; P = 0.60), major bleeding (18.2% vs 5.3%; P = .24), 30-day mortality, (42.4% vs 26.3%; P = .37), or in-hospital mortality (45.5% vs 36.8%; P = .58). The percentage of time activated partial thromboplastin time (aPTT) was within the therapeutic range was higher with bivalirudin (50% vs 85.7%; P = .007). CONCLUSIONS: This study suggests that UFH and bivalirudin are associated with similar rates of thrombosis, major bleeding, and mortality events in patients supported by ECMO. However, it was observed that bivalirudin consistently maintained aPTT within the therapeutic range in comparison to UFH.
Authors: René M'Pembele; Sebastian Roth; Aljoscha Metzger; Anthony Nucaro; Alexandra Stroda; Amin Polzin; Markus W Hollmann; Giovanna Lurati Buse; Ragnar Huhn Journal: Thromb J Date: 2022-07-28
Authors: Katherine Giuliano; Benjamin F Bigelow; Eric W Etchill; Ana K Velez; Chin Siang Ong; Chun W Choi; Errol Bush; Sung-Min Cho; Glenn J R Whitman Journal: Crit Care Explor Date: 2021-07-13
Authors: Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos Journal: Front Cardiovasc Med Date: 2021-07-07
Authors: Phillip S LoSavio; Tirth Patel; Matthew J Urban; Bobby Tajudeen; Peter Papagiannopoulos; Peter C Revenaugh; Inna Husain; Pete S Batra Journal: Laryngoscope Date: 2020-08-03 Impact factor: 2.970